SuperworthCencora, Inc. COR
Medical - Distribution, Healthcare
$317.25
+0.28%
- Market cap
- $60.5B
- PE
- 23.6×
- 10y median 20.9×
- Forward PE
- Price to sales
- 0.2×
- EV/EBIT
- 12.7×
- Revenue, 12 months
- $332.8B
- +5% on a year ago
- Net margin
- 0.8%
- Free cash flow yield
- 6.7%
Cencora trades at 23.6× trailing earnings, near its ten-year median. Revenue was $332.8B over the last twelve months, up 5% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $72.3B | $68.4B | $74.2B | $79.1B | $81.5B+13% | $75.5B+10% | $80.7B+9% | $83.7B+6% | $85.9B+6% | $78.4B+4% | $84.8B+5% | |
| Cost of revenue | $69.8B | $65.9B | $71.8B | $76.6B | $78.9B+13% | $72.4B+10% | $77.8B+8% | $80.8B+6% | $82.9B+5% | $74.8B+3% | $81.1B+4% |
| Gross profit | $2.5B | $2.5B | $2.4B | $2.5B | $2.6B+4% | $3.1B+21% | $2.9B+21% | $3B+19% | $3.1B+20% | $3.6B+17% | $3.6B+24% |
| SG&A | $1.4B | $1.4B | $1.4B | $1.5B | $1.5B+5% | $1.6B+15% | $1.7B+21% | $1.7B+17% | $1.8B+22% | $2B+24% | $2.1B+28% |
| $822.9M | $553.3M | $672.5M | $126.6M | $706.3M−14% | $1B+87% | $867.7M+29% | $18.5M−85% | $760.4M+8% | $1.1B+10% | $1.1B+29% | |
| Interest expense | $58.6M | $76.8M | $58.9M | $54.3M | $61.2M+4% | $132.3M+72% | $116.9M+98% | $109.4M+101% | $93.4M+53% | $154.3M+17% | $140.7M+20% |
| Pre-tax income | $783.4M | $467.1M | $628.3M | $125.2M | $620.4M−21% | $928.7M+99% | $896.3M+43% | −$187M | $708.6M+14% | $2.1B+125% | $996.4M+11% |
| $180.4M | $45.9M | $140.7M | $117.7M | $126.7M−30% | $211.2M+361% | $206.5M+47% | $146M+24% | $142.5M+13% | $459M+117% | $219.7M+6% | |
| Net income | $601.5M | $420.8M | $483.5M | $3.4M | $488.6M−19% | $717.9M+71% | $687.4M+42% | −$339.7M | $559.6M+15% | $1.6B+129% | $763.5M+11% |
| $2.98 | $2.09 | $2.42 | $0.02 | $2.50−16% | $3.68+76% | $3.52+46% | −$1.75 | $2.87+15% | $8.40+128% | $3.94+12% | |
| 201.8M | 201.2M | 200M | 200.3M | 195.2M−3% | 195.1M−3% | 195.2M−2% | 193.9M−3% | 195.3M+0% | 195.4M+0% | 193.9M−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Healthcare within ten times Cencora's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CORCencora, Inc. | $60.5B | 23.6× | 20.9× | 0.2× | +5% | 0.8% | |
| BSXBoston Scientific Corporation | $60.3B | 16.8× | 66.3× | 2.9× | +14% | 17.5% | |
| CAHCardinal Health, Inc. | $54B | 32.1× | 24.1× | 0.2× | +14% | 0.7% | |
| CICigna Corporation | $73.6B | 11.5× | 16.1× | 0.3× | +8% | 2.3% | |
| EWEdwards Lifesciences Corporation | $49.4B | 49.3× | 40.5× | 7.6× | +15% | 15.4% | |
| BDXBecton, Dickinson and Company | $49.1B | 54.3× | 47.3× | 2.4× | −3% | 4.5% | |
| REGNRegeneron Pharmaceuticals, Inc. | $76.4B | 18.3× | 19.8× | 4.9× | +9% | 27.9% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| HUMHumana Inc. | $47.6B | 37.5× | 20.5× | 0.3× | +18% | 0.9% | |
| MDLNMedline Inc. | $46.6B | 41.2× | 32.3× | 1.6× | +15% | — | |
| TEVATeva Pharmaceutical Industries Limited | $45.7B | 65.3× | 26.9× | 2.6× | +4% | 4.1% | |
| Peer median | $49.3B | 35.4× | 29.6× | 2.5× | +11% | 4.5% |
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .